NCT01376310View on ClinicalTrials.gov

GSK1120212 Rollover Study

PHASE2TerminatedINTERVENTIONAL

Enrollment

159

Participants

Timeline

Start Date

November 2, 2010

Primary Completion Date

January 18, 2018

Study Completion Date

January 18, 2018

Conditions

Cancer

Interventions

DRUG

GSK1120212

up to 2 mg/day

DRUG

Docetaxel + GSK1120212

dose as defined in the dose escalation protocol.

DRUG

Erlotinib + GSK1120212

dose as defined in the dose escalation protocol.

DRUG

Pemetrexed + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Carboplatin + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Nab-paclitaxel + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Gemcitabine + GSK1120212

dose as defined in the dose escalation protocol

DRUG

Everolimus + GSK1120212

dose as defined in the dose escalation protocol

Trial Locations (19)

10016

Novartis Investigative Site, New York

19104

Novartis Investigative Site, Philadelphia

31059

Novartis Investigative Site, Toulouse

34232

Novartis Investigative Site, Sarasota

37203

Novartis Investigative Site, Nashville

77030

Novartis Investigative Site, Houston

78229

Novartis Investigative Site, San Antonio

80045

Novartis Investigative Site, Aurora

84112

Novartis Investigative Site, Salt Lake City

85259

Novartis Investigative Site, Scottsdale

85338

Novartis Investigative Site, Goodyear

94805

Novartis Investigative Site, Villejuif

95817

Novartis Investigative Site, Sacramento

98405

Novartis Investigative Site, Tacoma

06510

Novartis Investigative Site, New Haven

M5G 2M9

Novartis Investigative Site, Toronto

9713 GZ

Novartis Investigative Site, Groningen

135-710

Novartis Investigative Site, Seoul

Unknown

Novartis Investigative Site, Taipei

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

All Listed Sponsors

lead

Novartis Pharmaceuticals

INDUSTRY